axitinib and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

axitinib has been researched along with Leukemia--Myelogenous--Chronic--BCR-ABL-Positive* in 1 studies

Other Studies

1 other study(ies) available for axitinib and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

Article	Year
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants includi European journal of medicinal chemistry, 2018, Dec-05, Volume: 160 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; Fusion Proteins, bcr-abl; Humans; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Mutation; Neoplasms, Experimental; Piperazines; Protein Kinase Inhibitors; Pyridines; Structure-Activity Relationship	2018

Article

Year

Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants includi

European journal of medicinal chemistry, 2018, Dec-05, Volume: 160

Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; Fusion Proteins, bcr-abl; Humans; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Mutation; Neoplasms, Experimental; Piperazines; Protein Kinase Inhibitors; Pyridines; Structure-Activity Relationship

2018